Lyra Therapeutics-Sponsored Study ‘LYR-220 System for Adult Subjects With Chronic Rhinosinusitis (CRS)’ Posted to Clinical Trials Website; Study is Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05035654
Lyra Therapeutics Q2 EPS $(0.85) Misses $(0.59) Estimate
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 51.79 percent decrease over losses of $(0.56) per share
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Lyra Therapeutics Announces Topline Results Of Pharmacokinetic Study Of LYR-210 In Patients With Chronic Rhinosinusitis; Says Results Support 505(b)(2) NDA Pathway For LYR-210
-- Results Support 505(b)(2) NDA Pathway for LYR-210
-- First U.S. Study of LYR-210 Enrolled Rapidly
WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen’s Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 22)
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 16 companies set new 52-week lows.